InterMune ASCENDs on new Phase III pirfenidone data
This article was originally published in Scrip
Executive Summary
InterMune will resubmit its new drug application (NDA) to the US FDA early in the third quarter of this year now that the company has positive data in hand from the Phase III ASCEND clinical trial for pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF).